CGON · CG Oncology, Inc.
Price
Snapshot
50 fields · last close| Market Cap | $6.00B |
| P/E | — |
| Float | 84.02M |
| Beta | 0.32 |
| Volatility 30D | 46.0% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Mid cap |
| Macro sensitivity | Low |
| Clavix score | 71.7 |
| Price | 65.01 |
| Change | −3.99% |
| Prev Close | 67.71 |
| Open | 66.10 |
| Day Low | 63.16 |
| Day High | 67.88 |
| Avg Vol | 1 |
| Avg $ Vol | $56.64M |
| 52W High | 80.97 |
| 52W Low | 35.80 |
| 52W Pos | 64.7% |
| From High | −19.71% |
| From Low | +81.59% |
| Max DD 1Y | −27.41% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +3.61% |
| SMA 50 | −5.19% |
| SMA 200 | −1.59% |
| RSI (14) | 57.5 |
| Vol 90D | 45.0% |
| Vol 1Y | 54.2% |
| 1Y Range | 36–81 |
| Daily bars | 549 |
| Perf Week | +5.86% |
| Perf Month | +6.40% |
| Perf Quarter | −9.54% |
| Perf Half Y | −0.44% |
| Perf Year | +61.60% |
| Perf YTD | +55.56% |
| Prev Day | −3.99% |
| Clavix | B- |
| Debt / Eq | 0.00 |
| Curr Ratio | 24.63 |
| Int Cover | -35,442.0× |
| FCF Margin | — |
| Rev Growth | +254.7% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 20 / 35 |
Clavix risk grade
regraded every trading dayCGON grades B-, 71.7 of 100. Steadiest on News Sentiment (69), most exposed on Price Stability (53, mixed). 2 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 20 of 35 in Biotechnology by Clavix score.
How rough the ride is
| CGON | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.32 | 0.49 |
| 30-day realized volatilityannualized, from daily closes | 46.0% | 46.0% |
| Max drawdown, past yearworst peak-to-trough fall | −27.4% | — |
| Typical daily movemedian absolute daily change | 2.03% | — |
| Days beyond ±3%of the last 252 sessions | 82 (33%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| CGON | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.32 | 0.49 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 54% of 35 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| CGON | |
|---|---|
| 1 week | +5.9% |
| 1 month | +6.4% |
| Year to date | +55.6% |
| 1 year | +61.6% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| CGON | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 23 since 25 Jun |
| Average score0 most bearish, 100 most bullish | 53 |
| Bullish · bearisharticles above 60 · below 40 | 13 · 9 |
| Directionarticles whose tone is improving vs worsening | 13 ↑ 9 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 35 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| CGON | |
|---|---|
| Revenue growthyear over year | +254.7% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openThe article describes CG Oncology’s cretostimogene treatment for non-muscle-invasive bladder cancer (NMIBC) as having a favorable tolerability profile and support from randomized Phase 3 data. It says CGON has more than $1 billion in cash, funding operations through 2029, while completion of the PIVOT-006 trial and a planned biologics license application (BLA), the FDA application needed to market the treatment, are imminent.
CG Oncology hired Isabel Kalofonos as Chief Commercial Officer in October 2026 to lead commercial strategy as the company prepares for the potential launch of its bladder cancer drug cretostimogene grenadenorepvec. The article notes her background in building sales organizations and bringing new oncology and rare disease medicines to market.
CG Oncology announced on October 13, 2026 that it appointed Isabel Kalofonos as Chief Commercial Officer. The company described her as a biopharmaceutical executive with more than 20 years of commercial leadership experience. The article body is truncated and does not provide further details about her background or start date.
CG Oncology announced on October 13, 2026 that it appointed Isabel Kalofonos as Chief Commercial Officer. Kalofonos brings more than 20 years of biopharmaceutical commercial leadership experience and will lead the company's commercial strategy ahead of the potential launch of its drug cretostimogene grenadenorepvec.
CG Oncology appointed Isabel Kalofonos as its new Chief Commercial Officer. She is described as having more than 20 years of commercial leadership experience in biopharmaceuticals.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| PTCT | PTC Therapeutics, Inc. | B | $5.76B | 8.34 | 0.49 | Compare |
| IONS | Ionis Pharmaceuticals, Inc. | B- | $6.67B | — | 0.36 | Compare |
| ERAS | Erasca, Inc. | C | $5.21B | — | 0.66 | Compare |
| ARWR | Arrowhead Pharmaceuticals, Inc. | C+ | $8.71B | — | 1.39 | Compare |
| CYTK | Cytokinetics, Incorporated | B+ | $8.84B | — | 0.40 | Compare |
| IOVA | Iovance Biotherapeutics Inc | D- | $3.94B | — | 0.84 | Compare |
| KRYS | Krystal Biotech, Inc. | B | $9.21B | 38.12 | 0.71 | Compare |
| TWST | Twist Bioscience Corporation | D | $9.24B | — | 2.30 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.